- Home
- PRLD vs NTWK Comparison
PRLD vs NTWK Comparison
Compare PRLD & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- NTWK
- Stock Information
- Founded
- PRLD 2016
- NTWK 1997
- Country
- PRLD United States
- NTWK United States
- Employees
- PRLD N/A
- NTWK N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- NTWK Computer Software: Prepackaged Software
- Sector
- PRLD Health Care
- NTWK Technology
- Exchange
- PRLD Nasdaq
- NTWK Nasdaq
- Market Cap
- PRLD 44.0M
- NTWK 50.8M
- IPO Year
- PRLD 2020
- NTWK 1998
- Fundamental
- Price
- PRLD $1.19
- NTWK $4.29
- Analyst Decision
- PRLD Strong Buy
- NTWK
- Analyst Count
- PRLD 3
- NTWK 0
- Target Price
- PRLD $4.00
- NTWK N/A
- AVG Volume (30 Days)
- PRLD 223.1K
- NTWK 28.0K
- Earning Date
- PRLD 11-05-2025
- NTWK 09-29-2025
- Dividend Yield
- PRLD N/A
- NTWK N/A
- EPS Growth
- PRLD N/A
- NTWK N/A
- EPS
- PRLD N/A
- NTWK 0.02
- Revenue
- PRLD $7,000,000.00
- NTWK $64,127,568.00
- Revenue This Year
- PRLD N/A
- NTWK N/A
- Revenue Next Year
- PRLD N/A
- NTWK N/A
- P/E Ratio
- PRLD N/A
- NTWK $208.89
- Revenue Growth
- PRLD N/A
- NTWK 9.18
- 52 Week Low
- PRLD $0.61
- NTWK $2.14
- 52 Week High
- PRLD $5.53
- NTWK $4.60
- Technical
- Relative Strength Index (RSI)
- PRLD 56.86
- NTWK 58.87
- Support Level
- PRLD $1.10
- NTWK $3.92
- Resistance Level
- PRLD $1.26
- NTWK $4.32
- Average True Range (ATR)
- PRLD 0.15
- NTWK 0.19
- MACD
- PRLD -0.00
- NTWK 0.00
- Stochastic Oscillator
- PRLD 70.65
- NTWK 93.14
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About NTWK NetSol Technologies Inc. Common Stock
NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions. Its products and services include NFS Ascent, NFS Digital, Leasepak Cloud, Business consultancy, and information security services among others. The firm has North America, Europe, and Asia-Pacific segments, of which the majority of the revenue is derived from Asia-Pacific. It derives revenue from licensing, customization, enhancements, and maintenance of its financial applications. The company promotes and sells its products under the Netsol financial suite.